^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    azacitidine

    i
    Other names: U-18496, Aza-C, NS 17, NS-17, Aza C, NSC-102816
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    20h
    Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML (clinicaltrials.gov)
    P3, N=60, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | N=30 --> 60 | Trial completion date: Mar 2025 --> Feb 2026
    Trial completion • Enrollment change • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    2d
    Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. (PubMed, Mol Metab)
    Overexpression of anti-apoptotic protein BCL-2 and hypermethylation are hallmarks of acute lymphoblastic leukemia (ALL) and can be pharmacologically addressed by venetoclax (VEN) and hypomethylating agents (HMA) such as azacytidine (AZA) or decitabine (DEC). AZA-induced metabolic suppression as well as overall anti-leukemic activity alone and in combination with VEN was generally weaker compared to DEC. Altogether, we herein demonstrate that combined VEN and HMA application acts synergistically and significantly reduces the leukemic burden in ALL cell lines via impairment of tumor cell metabolism and mitochondrial function.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    3d
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    3d
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    3d
    Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Liping Dou
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cytarabine • azacitidine • Epidaza (chidamide)
    3d
    A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | Trial completion date: Aug 2029 --> Jun 2026 | Trial primary completion date: Aug 2027 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Rezlidhia (olutasidenib)
    4d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    4d
    A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • Besremi (ropeginterferon alfa-2b-njft)
    4d
    Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations. (PubMed, Cureus)
    Azacitidine was administered after dialysis sessions, while venetoclax dosing was adjusted because of concomitant posaconazole prophylaxis. Approximately one year after diagnosis, relapsed AML was identified on peripheral blood flow cytometry. This case highlights the feasibility of venetoclax-based lower-intensity therapy in selected dialysis-dependent AML patients while underscoring the persistent therapeutic limitations and adverse prognosis associated with relapsed disease in this population.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • BCL6 (B-cell CLL/lymphoma 6) • BCOR (BCL6 Corepressor) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1)
    |
    RUNX1 mutation
    |
    Venclexta (venetoclax) • azacitidine • Noxafil (posaconazole)
    4d
    Role of exogenous supplementation of umbilical cord blood immune cells in reconstructing immune function and restoring hematopoietic function in elderly high-risk myeloid neoplasms patients (PubMed, Zhonghua Yi Xue Za Zhi)
    Based on treatment regimens, the patients were categorized into chemotherapy group ("3+7"regimen), demethylation therapy (HMA) group (decitabine-based therapy), and UCB group (venetoclax combined with azacitidine plus UCB reinfusion). Cytokine level analysis demonstrated that the direct co-culture group showed higher levels of TNF-α and IFN-γ, as well as lower levels of IL-6 compared to the control group (P<0.001). Immunocytes such as NK cells in UCB may promote immune function reconstruction and hematopoietic recovery in patients, thereby improving their prognosis.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • decitabine
    7d
    A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) (clinicaltrials.gov)
    P1, N=32, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    Venclexta (venetoclax) • azacitidine
    7d
    FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Fred Hutchinson Cancer Center
    New P1 trial • Minimal residual disease
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • WT1 (WT1 Transcription Factor)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    azacitidine